Released Aug 10, 2015, after the close
10-Q filed Aug 10, 2015, 41 days after period end · 0001144204-15-047801
Q2 2015 · 10-Q
Revenue$1.34M$1.34M −44.9% vs Q2 2014−21.0% vs Q1 2015
Net Income-$5.07M-$5.07M N/M vs Q2 2014N/M vs Q1 2015
EPS Diluted-$0.05-$0.05 N/M vs Q2 2014N/M vs Q1 2015
Gross Profit$1,111,000+2.8%
Operating Income-$5,584,000N/M
Operating Cash Flowderived-$5,346,000N/M
Free Cash Flowderived-$5,579,000N/M
Margins · derived
Gross margin83.2%+38.6 pt vs Q2 2014
Operating margin-418.0%−193.3 pt vs Q2 2014
Net margin-379.6%−127.2 pt vs Q2 2014
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2015 | Q2 2014 | Q2 2013 | Q2 2012 |
|---|---|---|---|---|
| Revenue | $1.34M | $2.43M | $2.26M | $26.11M |
| Net Income | -$5.07M | -$6.12M | -$6.84M | $9.64M |
| EPS Diluted | -$0.05 | -$0.07 | -$0.07 | $0.10 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR